Catalyst Pharmaceuticals Inc
$ 26.19
3.35%
14 Apr - close price
- Market Cap 3,114,600,000 USD
- Current Price $ 26.19
- High / Low $ 26.45 / 25.51
- Stock P/E 15.08
- Book Value 7.79
- EPS 1.68
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.16 %
- ROE 0.26 %
- 52 Week High 26.58
- 52 Week Low 19.05
About
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
Analyst Target Price
$34.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-18 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-08 | 2023-08-09 | 2023-05-10 |
| Reported EPS | 0.68 | 0.42 | 0.41 | 0.45 | 0.44 | 0.35 | 0.33 | 0.19 | 0.31 | -0.29 | 0.53 | 0.26 |
| Estimated EPS | 0.298 | 0.33 | 0.39 | 0.34 | 0.32 | 0.3 | 0.26 | 0.17 | 0.27 | -0.28 | 0.42 | 0.32 |
| Surprise | 0.382 | 0.09 | 0.02 | 0.11 | 0.12 | 0.05 | 0.07 | 0.02 | 0.04 | -0.01 | 0.11 | -0.06 |
| Surprise Percentage | 128.1879% | 27.2727% | 5.1282% | 32.3529% | 37.5% | 16.6667% | 26.9231% | 11.7647% | 14.8148% | -3.5714% | 26.1905% | -18.75% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.58 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CPRX
2026-04-13 17:20:00
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock rise by 1.60% to $25.34, outperforming the broader market on a strong trading day. Both the NASDAQ Composite Index and the Dow Jones Industrial Average also experienced gains. Despite the positive day, CPRX closed 4.67% below its 52-week high.
2026-04-12 00:39:10
Catalyst Pharmaceuticals (CPRX) has shown significant share price gains over multiple years, yet a Simply Wall St valuation suggests it remains undervalued. Using a Discounted Cash Flow analysis, the intrinsic value is estimated at $63.32 per share, indicating a 60.6% discount from its current trading price of $24.94. Additionally, its P/E ratio of 14.21x is below both the biotech industry average and its own Fair Ratio, further supporting the undervaluation claim.
2026-04-11 00:07:42
An investment of $1000 in Catalyst Pharmaceutical (CPRX) ten years ago would now be worth $22,456.14, representing a 2,145.61% gain. This significantly outperforms the S&P 500 (233.30%) and the price of gold (269.20%) over the same period. The company's success is attributed to its lead drug Firdapse, new acquisition Agamree, and strategic diversification efforts, with analysts expecting further upside.
2026-04-10 17:20:00
Catalyst Pharmaceuticals Inc. (CPRX) stock decreased by 2.58% on Friday, closing at $24.94. This underperformance occurred during a mixed trading session where the NASDAQ Composite Index rose, and the Dow Jones Industrial Average fell. The stock's decline ended a four-day winning streak.
2026-04-10 11:30:59
Catalyst Pharmaceuticals Inc (CPRX) is highlighted as a top "Affordable Growth" stock, combining strong earnings and revenue growth with reasonable valuation multiples. The biopharmaceutical company specializes in rare diseases, demonstrating robust profitability and a debt-free financial statement. This profile suggests CPRX offers a balance of growth potential and financial stability, making it an attractive option for investors.
2026-04-09 17:20:00
Shares of Catalyst Pharmaceuticals Inc. (CPRX) rose 1.15% to $25.60 on Thursday, outperforming the NASDAQ Composite Index and the Dow Jones Industrial Average on a strong trading day. This marks the stock's fourth consecutive day of gains. The article highlights the company's positive performance relative to the broader market.
